Clinical trial · Interventional
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
Parallel Control Study of Electroacupuncture Stimulation the Acupoints of Yangming Channel on Prevention and Treatment of Oxaliplatin Neurotoxicity During the Peri-chemotherapy Period
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The clinical trail of electroacupuncture combined with oxaliplatin regimen on gastrointestinal carcinoma.This trail is randomized controled.Patients are diagnosed gastrointestinal cancer based on pathology or cell biology.They are randomized into 2 groups:both groups receive Oxaliplatin regimen.The treatment group receives electroacupuncture in addition to the chemotherapy.The control group only receive the same chemotherapy with the treatment group.Both group have the same adjuvant therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS | 0.90 |
| Neurotoxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| electro-acupuncture | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- electroacupuncture group
- description
- The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
- interventionNames
- Other: electro-acupuncture
- type
- NO_INTERVENTION
- label
- control group
- description
- The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
Primary outcomes (1)
- measure
- Levi sensory nerve toxicity classification standard
- timeFrame
- every cycle of chemotherapy (measure 3 cycles, each cycle is 21 days), up to 3 months]
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age:18-80 ; 2. male and female ; 3. signed the informed consent form; 4. Eastern Cooperative oncology Group(ECOG)O-2,life expectancy more than 3 months; 5. Indication for Chemotherapy,no contraindication; 6. First time chemotherapy or at least 6 months after last chemotherapy and radiotherapy; 7. At least 8 weeks after last biotherapy; 8. Surgery:had not received transplantation surgery,at least 2 weeks after last major surgery. Exclusion Criteria: 1. Chemotherapy is contraindicated; 2. Having the primary disease can cause the neuropathy; 3. A history of other malignant tumor in recent 5 years; 4. Less than 6 months after last chemotherapy or radiotherapy; 5. Less than 8 weeks after last biotherapy; 6. Being afraid of acupuncture seriously; 7. Had received transplantation surgery,less than 2 weeks after last major surgery; 8. Other researchers think is not suitable for this clinical trail.
References
Publications (0)
Data not yet available